Taxol: mechanisms of action and resistance
- PMID: 7912530
Taxol: mechanisms of action and resistance
Abstract
Information on the mechanisms of action and of resistance to Taxol, as well as new data from our laboratory on the promoter regions of the genes that encode P-glycoprotein in a murine Taxol-resistant cell line, is discussed. Taxol induces the formation of stable bundles of microtubules, thereby interfering with the normal function of cellular microtubules. The drug can induce the multidrug-resistance (MDR) phenotype that includes the overproduction of P-glycoprotein, a membrane glycoprotein that acts as a drug efflux pump. In human tumors resistant to Taxol, P-glycoprotein could be responsible for maintaining the drug below cytotoxic levels. Analyses of the MDR promoters that are involved in P-glycoprotein expression and overproduction revealed an interesting recombination event in a Taxol-resistant cell line. As an important new clinical agent for the treatment of malignancies, Taxol requires further mechanistic investigations at the preclinical level.
Similar articles
-
Characterization of a human myeloid leukemia cell line highly resistant to taxol.Leukemia. 1994 Mar;8(3):465-75. Leukemia. 1994. PMID: 7907395
-
In vitro evaluation of chemosensitizers for clinical reversal of P-glycoprotein-associated Taxol resistance.J Natl Cancer Inst Monogr. 1993;(15):63-7. J Natl Cancer Inst Monogr. 1993. PMID: 7912531
-
Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin.Cancer Res. 1993 Nov 15;53(22):5487-93. Cancer Res. 1993. PMID: 8106148
-
Multidrug resistance mediated by P-glycoprotein in haematological malignancies.Neth J Med. 1993 Jun;42(5-6):218-31. Neth J Med. 1993. PMID: 8104318 Review.
-
Molecular targets in oncology: implications of the multidrug resistance gene.Pharmacotherapy. 1993 Mar-Apr;13(2):88-109. Pharmacotherapy. 1993. PMID: 8097038 Review.
Cited by
-
A promising strategy for overcoming MDR in tumor by magnetic iron oxide nanoparticles co-loaded with daunorubicin and 5-bromotetrandrin.Int J Nanomedicine. 2011;6:2123-31. doi: 10.2147/IJN.S24309. Epub 2011 Sep 27. Int J Nanomedicine. 2011. PMID: 22114476 Free PMC article.
-
A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma.Melanoma Res. 2016 Dec;26(6):604-608. doi: 10.1097/CMR.0000000000000296. Melanoma Res. 2016. PMID: 27540836 Free PMC article. Clinical Trial.
-
Paclitaxel-Based Chemotherapy Targeting Cancer Stem Cells from Mono- to Combination Therapy.Biomedicines. 2021 May 2;9(5):500. doi: 10.3390/biomedicines9050500. Biomedicines. 2021. PMID: 34063205 Free PMC article. Review.
-
Inhibition of mdr1 by G-quadruplex oligonucleotides and reversal of paclitaxel resistance in human ovarian cancer cells.Tumour Biol. 2015 Aug;36(8):6433-43. doi: 10.1007/s13277-015-3333-2. Epub 2015 Mar 24. Tumour Biol. 2015. PMID: 25801244
-
A Review of Paclitaxel and Novel Formulations Including Those Suitable for Use in Dogs.J Vet Intern Med. 2015 Jul-Aug;29(4):1006-12. doi: 10.1111/jvim.12596. J Vet Intern Med. 2015. PMID: 26179168 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Research Materials